Prevalence of Sarcopenia and Its Geriatric Features

NCT02664376 | Completed

• 1 other identifier: CHUB-sarcopenia
• Study Type: observational
• Target: 834
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to determine the prevalence of sarcopenia in a geriatric hospital ward. Sarcopenia is defined by a loss of muscle mass, loss of muscle strength and loss of muscle quality. It is a geriatric syndrome that, to this date, is not systematically tracked in clinical practice. In order to detect sarcopenia, the investigators will use the operational definition proposed by the European Working Group (EWGSOP) involving the measure of three parameters, namely the speed of walking, the muscle strength and the measurement of the muscular mass.

Conditions

Sarcopenia

Keywords

sarcopenia; geriatry

Outcome Measures

Primary Outcomes (1)

• Prevalence of sarcopenia

  Sarcopenia detection will be performed at the end of each hospitalization stay in unit 83 of the CHU Brugmann Hospital (Geriatry Department)

  From 10/01/2016 till 30/03/2017 (up to 15 months)

Secondary Outcomes (1)

• Percentage of hospitalized patients unable to perform the sarcopenia detection test

  From 10/01/2016 till 30/03/2017 (up to 15 months)

Study Arms (1)

Geriatric ward population

Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.

Other: Sarcopenia detection

Interventions

Sarcopenia detection OTHER

The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made: * Muscle mass measurement by dual energy X-ray absorptiometry (DEXA). * Walking speed measurement * Hand grip test A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low. Data regarding the geriatric characteristics of this sarcopenic population will be collected.

Geriatric ward population

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Each patient over 65 years admitted to the unit 83 of the Geriatric Department, CHU Brugmann Hospital, from 10/01/2016 till 30/03/2017 undergoes a comprehensive geriatric assessment at the end of its hospitalisation stay. The screening for sarcopenia is part of this geriatric assessment.

You may qualify if:

• To be admitted in the unit 83 of the Geriatric Departement of the CHU Brugmann hospital, from 10/01/2016 till 30/03/2017.

You may not qualify if:

• Patients unable to consent or without representatives
• Patients unable to perform the hand- grip test, the walk test or measurement of the body components by DEXA
• Patients in severe pain
• Bedridden patients
• Patients for which a clear therapeutic abstention has been established
• Language barriere that cannot be overcome
• Patients unable to walk without the help of a third person

Sponsors & Collaborators

• Brugmann University Hospital: lead

Study Sites (1)

CHU Brugmann

Brussels, 1020, Belgium

Location

Related Publications (4)

• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.

  PMID: 20392703 BACKGROUND

• Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998 Apr 15;147(8):755-63. doi: 10.1093/oxfordjournals.aje.a009520.

  PMID: 9554417 BACKGROUND

• Cesari M, Kritchevsky SB, Newman AB, Simonsick EM, Harris TB, Penninx BW, Brach JS, Tylavsky FA, Satterfield S, Bauer DC, Rubin SM, Visser M, Pahor M; Health, Aging and Body Composition Study. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009 Feb;57(2):251-9. doi: 10.1111/j.1532-5415.2008.02126.x.

  PMID: 19207142 BACKGROUND

• Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi AM, Rantanen T, Guralnik JM, Ferrucci L. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985). 2003 Nov;95(5):1851-60. doi: 10.1152/japplphysiol.00246.2003.

  PMID: 14555665 BACKGROUND

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Robin Barré, MD

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

• Murielle Surquin, MD

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

• Florence Benoît, MD

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

• Marie Claessens, MD

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of clinic

Study Record Dates

• First Submitted: January 19, 2016
• First Posted: January 27, 2016
• Study Start: January 1, 2016
• Primary Completion: January 18, 2018
• Study Completion: January 18, 2018
• Last Updated: January 26, 2018

Record last verified: 2018-01

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)